Drug firm Cadila Healthcare today reported a 47.11 per cent rise in its consolidated net profit to Rs 353.39 crore for the first quarter ended June 30, mainly on account of robust sales.
The company had posted a net profit after taxes, minority interest and share of profit/(loss) of associates of Rs 240.21 crore for the corresponding period of the previous fiscal, Cadila Healthcare said.
Consolidated total income from operations of the company rose to Rs 2,500.65 crore during the quarter under consideration as against Rs 2,050.12 crore in the year ago period.
Also Read
The company's formulations business in the US grew by 37 per cent during the quarter.
During the quarter, the group filed 6 additional ANDAs with the US Food and Drug Administration (USFDA) and launched one new product in the US, Cadila Healthcare said.
In the Indian formulations market, the company launched 12 new products, it added.
In a separate filing on BSE, Cadila Healthcare said its Board of Directors has considered and approved the sub- division (split) of one equity share of the company having a face value of Rs 5 into five equity shares of face value of Rs 1 each.
Shares of Cadila Healthcare today closed at Rs 2003.50 apiece on BSE, up 4.44 per cent.
